WASHINGTON (dpa-AFX) - DISCO Pharmaceuticals GmbH on Thursday announced a strategic collaboration and option-to-license deal with AbbVie (ABBV) to discover and develop novel AND-gated bispecific therapeutics for solid tumors with high unmet medical need.
Under the terms, DISCO will receive $40 million in upfront payments, and eligible for up to $2.5 billion in option, development, and other milestone payments, and tiered royalties on net sales.
Mark Manfredi, CEO of DISCO Pharmaceuticals, said: 'Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue, thus offering a potentially differentiated path in precision oncology. Our DISCOtech platform's unique ability to identify tumor-selective target pairs provides the foundation for therapies with the potential for a wider therapeutic window.'
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News



